加载中
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
收盘时
US$6.43
+US$0.265 · +4.30%
盘后
US$6.34
−US$0.09 · -1.40%
10月13日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
日内区间
当前US$6.43
52周区间
当前US$6.43
盘中时间采用ET。市场数据可能有所延迟。
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
日内区间
当前US$6.43
52周区间
当前US$6.43
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 6808.8万 USD | — | — | — | 47.9万 USD |
| 毛利 | −6808.8万 USD | — | — | — | −47.9万 USD |
| 研究与开发 | 1750万 USD | 7068.2万 USD | 9379万 USD | 6146.4万 USD | 4279.4万 USD |
| 销售、一般及管理费用 | 1667.8万 USD | 2609.3万 USD | 3330.4万 USD | 3255.2万 USD | 2122.8万 USD |
| 营业费用 | 3417.8万 USD | 1.01亿 USD | 1.25亿 USD | 1.04亿 USD | 6354.3万 USD |
| 利息收入 | — | 396.2万 USD | 763.7万 USD | 321.6万 USD | 33.7万 USD |
| 利息支出 | — | — | — | 2431.6万 USD | 3000 USD |
| 折旧和摊销 | 97.2万 USD | 97万 USD | 96.9万 USD | 84.5万 USD | 47.9万 USD |
| 营业利润 | −1.02亿 USD | −1.01亿 USD | −1.25亿 USD | −1.04亿 USD | −6402.2万 USD |
| 净利润 | −1.06亿 USD | −9694万 USD | −1.18亿 USD | −9563.9万 USD | −5485.3万 USD |
公司数据更新于 2026年10月14日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年9月18日 | 1:10 | — | — |
已生效 2025年9月18日
1:10
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI145.14万0.00%2.3万亿 USD0.03%US$381.32-0.07%
Simplify Propel Opportunities ETFSURI92.03万1.22%7546.43万 USD2.82%US$17.09-0.96%
Vanguard Extended Market ETFVXF65.25万0.00%954亿 USD0.05%US$232.54-0.42%
iShares Micro-Cap ETFIWC12.58万0.01%13.07亿 USD0.60%US$179.6-1.13%
U.S. Micro Cap Portfolio ETFDFMC2.33万0.00%75.44亿 USD0.43%US$57.78+0.14%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR2.24万0.00%455.76亿 USD0.17%US$84.455+0.03%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.03万0.00%61.96亿 USD0.26%US$68.51+0.28%
Dimensional - US Core Equity 2 ETFDFAC3366.090.00%885.59亿 USD0.21%US$45.35+0.09%Vanguard Morningstar Total Stock Market ETFVTISimplify Propel Opportunities ETFSURIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCU.S. Core Equity 1 Portfolio ETF Class SharesDCORU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
